Tetsuji Matsudaira

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignee: Mitsubishi Tanabe Pharma Corporation. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tetsuji Matsudaira. Retrieved from https://idiyas.com/inventor/tetsuji-matsudaira

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 60.0

CIPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 6.2

ph-index = 1

Forward Citations = 4(Granted Patents)

Company Filing History:

5 out of 263

Mitsubishi Tanabe Pharma Corporation

patents

Years Active: 2009-2024

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12102641 - Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof (2024-10-01),

2. 11890288 - Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof (2024-02-06),

3. 10407408 - Imide derivatives and use thereof as medicine (2019-09-10),

4. 8119626 - Oxime derivative and preparations thereof (2012-02-21),

5. 7514439 - Oxime derivative and preparations thereof (2009-04-07),

Title: Tetsuji Matsudaira: Innovator in Pharmaceutical Chemistry

Introduction

Tetsuji Matsudaira is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target cancer treatment. With a total of 5 patents to his name, Matsudaira's work is recognized for its innovative approach to drug development.

Latest Patents

One of Matsudaira's latest patents involves a sulfonamide or sulfinamide compound that induces BRD4 protein degradation. This compound is noted for its potential as a therapeutic agent for cancer. The patent details a compound or a pharmaceutically acceptable salt that demonstrates superior action in inducing the degradation of BRD4 protein, which is crucial in cancer therapy.

Career Highlights

Matsudaira is currently associated with Mitsubishi Tanabe Pharma Corporation, where he continues to advance his research in pharmaceutical innovations. His work has been instrumental in developing new therapeutic strategies that could significantly impact cancer treatment.

Collaborations

Matsudaira collaborates with talented coworkers, including Maiko Hamada and Kazutoshi Sugawara. Their combined expertise contributes to the innovative research environment at Mitsubishi Tanabe Pharma Corporation.

Conclusion

Tetsuji Matsudaira's contributions to pharmaceutical chemistry highlight his role as a key innovator in cancer treatment. His ongoing research and patent developments continue to pave the way for new therapeutic options.

Profile summary based on public USPTO records.